10-Q: Shuttle Pharma Reports Wider Q2 Loss, Raises Capital Amid Going Concern Doubts

Shuttle Pharmaceuticals Holdings, Inc. reported a significantly wider net loss in Q2 2025, raising $8.9 million in net proceeds from equity financings but still facing substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the six months ended June 30, 2025, increased by 80% to $6.8 million, compared to $3.8 million for the same period in 2024.
• Operating expenses surged by 139% to $6.9 million for the six months ended June 30, 2025, driven by increased research and development and general and administrative costs.
• Research and development expenses rose 111% to $2.6 million, primarily due to drug product production and the initiation of clinical trials.
• General and administrative expenses increased 364% to $2.9 million, largely due to $2.0 million in investor relations advertising costs.
• The company successfully raised $5.0 million net from a March 2025 public offering and $3.9 million net from a June 2025 private placement.
• Cash and cash equivalents increased to $4.8 million as of June 30, 2025, from $1.9 million at December 31, 2024.
• Working capital improved to $3.5 million as of June 30, 2025, from $0.7 million at December 31, 2024.
• The company effectuated a 1-for-25 reverse stock split on June 16, 2025, and regained Nasdaq minimum bid price compliance on July 2, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern for the next twelve months, as current resources are not expected to be sufficient.
• Phase II clinical study for Ropidoxuridine commenced in October 2024, following FDA recommendations for dose optimization.

Sentiment

Score: 3

Explanation: While the company successfully raised capital and progressed its clinical trials, the significantly widened net loss, increased cash burn, and explicit 'going concern' warning indicate severe financial distress and high operational risk. The need for two reverse stock splits in less than a year also reflects underlying stock price weakness.

Positives

• Successful completion of two equity financings in March and June 2025, raising a combined $8.9 million in net proceeds.
• Regained compliance with Nasdaq's minimum bid price requirement on July 2, 2025, following a 1-for-25 reverse stock split.
• Progress in Ropidoxuridine clinical development, with drug product manufactured, formulated, and distributed to clinical trial sites, and Phase II study commenced.
• Remediation of a previously disclosed material weakness in internal controls related to R&D expense classification.
• Increased cash and cash equivalents to $4.8 million and working capital to $3.5 million as of June 30, 2025.

Negatives

• Net loss significantly widened by 80% to $6.8 million for the six months ended June 30, 2025, compared to the prior year.
• Total operating expenses increased by 139% to $6.9 million, indicating a substantial increase in operational burn rate.
• General and administrative expenses surged by 364%, largely due to $2.0 million spent on investor relations advertising.
• Cash used in operating activities increased by 123% to $5.9 million for the six months ended June 30, 2025.
• The company's existing cash resources, recent equity proceeds, and available revolving note funds are not expected to be sufficient to fund operations and clinical trials through the next twelve months.
• Substantial doubt about the company's ability to continue as a going concern.
• Identified material weaknesses in internal controls over financial reporting persist, including limited written policies, insufficient review and segregation of duties, and IT general control issues.
• Delay in filing the registration statement for the June 2025 private placement shares, though attributed to investor requests.

Risks

• Going Concern: The company has incurred losses since inception and does not expect to generate positive cash flows in the near future, raising substantial doubt about its ability to continue as a going concern within one year.
• Funding Risk: The company's ability to continue operations is dependent on successfully raising additional equity or debt financing to fund ongoing operations, clinical trials, and commercialization.
• Clinical Trial Risks: There is no assurance that the company will not encounter problems in its clinical trials that could cause delays or suspensions by the company or the FDA.
• Regulatory Approval Risk: Products must undergo rigorous preclinical and clinical testing and an extensive regulatory approval process by the FDA, with no assurance of approval.
• Intellectual Property Risk: Success depends on obtaining patents, product license rights, maintaining trade secrets, and operating without infringing on others' rights, with no assurance that patents will not be challenged, invalidated, or circumvented.
• Nasdaq Listing Risk: While compliance was regained, the need for two reverse stock splits in less than a year highlights ongoing challenges in maintaining the minimum bid price requirement.
• Internal Control Weaknesses: Material weaknesses in internal controls over financial reporting, including limited written policies, insufficient review and segregation of duties, and IT general control issues, could adversely affect the company's ability to record, process, summarize, and report financial information.
• Litigation Risk (Boustead): Boustead Securities, LLC has asserted ROFR rights and claimed entitlement to compensation, which could lead to future legal proceedings or financial obligations.

Future Outlook

The company does not expect to generate positive cash flows from operating activities in the near future. Its ability to continue as a going concern is dependent on successfully raising additional equity or debt financing to fund ongoing operations, conduct clinical trials, and bring a drug candidate to commercialization. The existing cash resources, recent equity offering proceeds, and financing available under the revolving note are not expected to provide sufficient funds to carry out operations and clinical trials through the next twelve months.

Management Comments

• Our unaudited condensed consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.
• The Company has incurred losses since inception and had a net loss of approximately $6.8 million and no revenues for the six months ended June 30, 2025 and working capital of approximately $3.5 million as of June 30, 2025.
• The Company does not expect to generate positive cash flows from operating activities in the near future.
• The Companys existing cash resources, the cash received from the equity offering, and financing available under the revolving note are not expected to provide sufficient funds to carry out the Companys operations and clinical trials through the next twelve months.
• These conditions raise substantial doubt about the Companys ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.
• Management is committed to maintaining a strong internal control environment.
• Our remediation efforts, including those noted above, were completed and the related controls were in place for a sufficient period of time to conclude that this material weakness [R&D expense classification] was remediated as of June 30, 2025.

Industry Context

The company operates in the highly capital-intensive and regulated biotechnology and pharmaceutical industry, specifically focusing on cancer therapies and radiation sensitization. Its continued reliance on external financing for research, development, and clinical trials, coupled with a lack of revenue, is typical for a discovery and development stage pharmaceutical company. The challenges in maintaining Nasdaq listing requirements and the need for multiple reverse stock splits highlight the inherent volatility and investor sentiment risks often associated with early-stage biotech firms. The focus on Ropidoxuridine's Phase II trial and HDAC6 inhibitors aligns with broader industry trends in targeted cancer therapies and immunotherapies.

Management Changes

Corporate Governance

Legal Proceedings

• There are no material pending legal proceedings, to which the Company or any of its subsidiaries is a party or of which any of their property is the subject.
• Boustead Securities, LLC has asserted ROFR rights and claimed entitlement to compensation, but as of the reporting date, no conditions indicate a loss has been incurred, nor is a loss probable and reasonably estimable.

Related Party Transactions

• Accrued interest payable to related parties: $590 as of June 30, 2025.
• Notes payable to related parties: $65,326 outstanding as of June 30, 2025.
• Convertible notes payable to related parties: $127,689 outstanding as of June 30, 2025.
• An officer of the company provided a $250,000 loan on October 14, 2024, as part of the senior convertible note offering.
• An officer of the company was issued a $250,000 promissory note on September 4, 2024.
• Dr. Anatoly Dritschilo (former CEO and Chief Scientific Officer) invested $237,500 in the October 2024 senior secured convertible note offering.

Stakeholder Impact

• Shareholders: Significant dilution from recent equity raises and reverse stock splits. Continued risk of further dilution due to ongoing need for capital. Share price volatility due to Nasdaq compliance issues and going concern doubts.
• Employees: Management changes (CEO, CSO, VP Regulatory) could impact morale and strategic direction. Stock-based compensation is a significant component of remuneration.
• Creditors: Revolving note and convertible notes carry high interest rates (18% and 14.5% respectively), indicating high credit risk. Security interests and liens on assets provide some protection.
• Customers/Patients: Progress in clinical trials for Ropidoxuridine offers potential future benefits, but the company's going concern status introduces uncertainty regarding long-term product development and availability.
• Suppliers/CROs: Increased R&D expenses and commitments to CROs (e.g., Theradex Systems) indicate active engagement, but the company's liquidity issues could pose payment risks.

Next Steps

• Continue to raise additional equity or debt financing to fund ongoing operations and clinical trials.
• Continue the Phase II clinical study for Ropidoxuridine, incorporating FDA recommendations for randomized dose optimization.
• Advance HDAC6 inhibitor (SP-2-225) preclinical development.
• Proceed with plans for clinical validation and potential commercialization of Ropidoxuridine as a radiation sensitizer and the PC-RAD Test.
• Continue remediation efforts for identified material weaknesses in internal controls over financial reporting.
• Monitor and evaluate the effectiveness of internal controls and procedures on an ongoing basis.
• The Revolving Note Agreement matures on February 28, 2026.
• The UCSF Sponsored Research Agreement is effective for one year from December 16, 2024, and may be extended.
• RSUs granted on August 8, 2025, will vest over a three-year period (one-third on each anniversary) for Board members and CFO, and six months from grant date for an additional CFO grant.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, evidenced by significant and widening net losses, a high cash burn rate, and an explicit statement that current funds are insufficient for the next twelve months. While recent capital raises provide temporary relief, they come with significant dilution and high interest rates on debt. The need for two reverse stock splits in less than a year to maintain Nasdaq compliance further underscores severe underlying issues. Persistent material weaknesses in internal controls add to the risk profile. Given the high operational risk, lack of revenue, and ongoing funding challenges, a seasoned investor would likely view this as a high-risk, speculative investment with a strong likelihood of further value erosion.

Keywords

Shuttle Pharmaceuticals, SHPH, biotechnology, cancer therapy, radiation sensitizer, Ropidoxuridine, HDAC inhibitors, clinical trials, SEC filing, 10-Q, financial results, going concern, equity financing, Nasdaq compliance, pharmaceutical development, oncology